awmsg logo



umeclidinium (Incruse®)


Reference No. 1352

Publication date:
13/01/2015


Appraisal information

umeclidinium (Incruse®) 55 micrograms inhalation powder


Company: GlaxoSmithKline
BNF category: Respiratory system
NMG meeting date: 15/10/2014
AWMSG meeting date: 12/11/2014
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 3514
Ministerial ratification: 09/01/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Umeclidinium (Incruse®) is recommended as an option for use within NHS Wales as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download